Hyaluronic acid-paclitaxel: Effects of intraperitoneal administration against CD44(+) human ovarian cancer xenografts

Cancer Chemotherapy and Pharmacology

Volumn 68, Issue 1, 2011, Pages 107-116

  De Stefano, Ilaria ^a   Battaglia, Alessandra ^a   Zannoni, Gian Franco ^a   Prisco, Maria Grazia ^a   Fattorossi, Andrea ^a   Travaglia, Daniele ^a   Baroni, Silvia ^a   Renier, Davide ^b   Scambia, Giovanni ^a   Ferlini, Cristiano ^a   Gallo, Daniela ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Fidia Advanced Biopolymers   (Italy)

Author keywords

CD44; Hyaluronan; Mice; Ovarian cancer; Paclitaxel

Indexed keywords

ANTINEOPLASTIC AGENT; CA 125 ANTIGEN; HERMES ANTIGEN; HYALURONIC ACID PACLITAXEL BIOCONJUGATE; ONCOFID P; PACLITAXEL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASCITES; BLOOD; BONE MARROW; BONE MARROW TOXICITY; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CANCER TRANSPLANTATION; CELL STRAIN OVCAR 3; CELL STRAIN SKOV 3; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEMATOPOIESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTRAABDOMINAL METASTASIS; MAXIMUM TOLERATED DOSE; METASTASIS; MOUSE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SPLEEN;

ANIMALS; ANTIGENS, CD44; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CA-125 ANTIGEN; CELL LINE, TUMOR; FEMALE; HUMANS; HYALURONIC ACID; INJECTIONS, INTRAPERITONEAL; MICE; MICE, INBRED BALB C; OVARIAN NEOPLASMS; PACLITAXEL; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79959588621     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-010-1462-2     Document Type: Article

References (34)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics. CA Cancer J Clin 59:225-249
2. Ferlay J, Autier P, Boniol M, Heanue M, Colombet M, Boyle P (2007) Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol 18:581-592
3. Markman M (2008) The promise and perils of 'targeted therapy' of advanced ovarian cancer. Oncology 74:1-6
4. Landrum LM, Gold MA, Moore KN, Myers TK, McMeekin DS, Walker JL (2008) Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates. Gynecol Oncol 108:342-347 (Pubitemid 351181442)
5. Petignat P, du Bois A, Bruchim I, Fink D, Provencher DM (2007) Should intraperitoneal chemotherapy be considered as standard first-line treatment in advanced stage ovarian cancer? (Review). Crit Rev Oncol Hematol 62:137-147
6. de Bree E, Theodoropoulos PA, Rosing H, Michalakis J, Romanos J, Beijnen JH, Tsiftsis DD (2006) Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside. Cancer Treat Rev 32:471-482 (Pubitemid 44321352)
7. Markman M (2008) Antineoplastic agents in the management of ovarian cancer: current status and emerging therapeutic strategies (Review). Trends Pharmacol Sci 29:515-519
8. de Bree E, Rosing H, Michalakis J, Romanos J, Relakis K, Theodoropoulos PA, Beijnen JH, Georgoulias V, Tsiftsis DD (2006) Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination. Eur J Surg Oncol 32:666-670 (Pubitemid 44087882)
9. Mamot C, Drummond DC, Hong K, Kirpotin DB, Park JW (2003) Liposome-based approaches to overcome anticancer drug resistance (Review). Drug Resist Updat 6:271-279 (Pubitemid 37493783)
10. Lesley J, Hascall VC, Tammi M, Hyman R (2000) Hyaluronan binding by cell surface CD44. J Biol Chem 275:26967-26975
11. Entwistle J, Hall CL, Turley EA (1996) HA receptors: regulators of signalling to the cytoskeleton. J Cell Biochem 61:569-577 (Pubitemid 26240134)
12. Kayastha S, Freedman AN, Piver MS, Mukkamalla J, Romero-Guittierez M, Werness BA (1999) Expression of the hyaluronan receptor, CD44S, in epithelial ovarian cancer is an independent predictor of survival. Clin Cancer Res 5:1073-1076 (Pubitemid 29233221)
13. Maxwell CA, McCarthy J, Turley E (2008) Cell-surface and mitotic-spindle RHAMM: moonlighting or dual oncogenic functions? J Cell Sci 121:925-932
14. Chen H, Hao J, Wang L, Li Y (2009) Coexpression of invasive markers (uPA, CD44) and multiple drug-resistance proteins (MDR1, MRP2) is correlated with epithelial ovarian cancer progression. Br J Cancer 101:432-440
15. Leonelli F, La Bella A, Migneco LM, Bettolo RM (2008) Design, synthesis and applications of hyaluronic acid-paclitaxel bioconjugates. Molecules 13:360-378
16. Wilson JG (1997) Adhesive interactions in hemopoiesis (Review). Acta Haematol 97:6-12
17. Ghaffari S, Smadja-Joffe F, Oostendorp R, Lévesque JP, Dougherty G, Eaves A, Eaves C (1999) CD44 isoforms in normal and leukemic hematopoiesis. Exp Hematol 27:978-993 (Pubitemid 29275386)
18. Chan JY, Watt SM (2001) Adhesion receptors on haematopoietic progenitor cells. Br J Haematol 112:541-557 (Pubitemid 32222821)
19. Banzato A, Bobisse S, Rondina M, Renier D, Bettella F, Esposito G, Quintieri L, Meléndez-Alafort L, Mazzi U, Zanovello P, Rosato A (2008) A paclitaxel-hyaluronan bioconjugate targeting ovarian cancer affords a potent invivo therapeutic activity. Clin Cancer Res 14:3598-3606
20. Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer 37:1590-1598 (Pubitemid 32778603)
21. Rosato A, Banzato A, De Luca G, Renier D, Bettella F, Pagano C, Esposito G, Zanovello P, Bassi P (2006) HYTAD1-p20: a new paclitaxel-hyaluronic acid hydrosoluble bioconjugate for treatment of superficial bladder cancer. Urol Oncol 24:207-215
22. Motulsky HJ, Ransnas LA (1987) Fitting curves to data using nonlinear regression: a practical and nonmathematical review. FASEB J 1:365-374
23. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) (1998) Guidelines for the welfare of animals in experimental neoplasia (second edition). Br J Cancer 77:1-10
24. Ferlini C, Cicchillitti L, Raspaglio G, Bartollino S, Cimitan S, Bertucci C, Mozzetti S, Gallo D, Persico M, Fattorusso C, Campiani G, Scambia G (2009) Paclitaxel directly binds to Bcl-2 and functionally mimics activity of Nur77. Cancer Res 69:6906-6914
25. Gandon G, Quillien V, Godey F (2004) Evaluation of the new access OV monitor assay for the quantitative determination of CA 125 antigen levels. Immuno-analyse and Biologie specialisée 19:228-234 (Pubitemid 39286195)
26. Holdenrieder S, Molina R, Gion M, Gressner A, Troalen F, Auge JM, Zancan M, Wycislo M, Stieber P (2008) Alternative antibody for the detection of CA 125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the access OV monitor assay on the UniCel DxI 800 immunoassay system. Clin Chem Lab Med 46:588-599 (Pubitemid 351749107)
27. Fleuren GJ, Nap M, Aalders JG, Trimbos JB, de Bruijn HW (1987) Explanation of the limited correlation between tumor CA 125 content and serum CA 125 antigen levels in patients with ovarian tumors. Cancer 60:2437-2442 (Pubitemid 17157250)
28. Duffy MJ, Bonfrer JM, Kulpa J, Rustin GJ, Soletormos G, Torre GC, Tuxen MK, Zwirner M (2005) CA125 in ovarian cancer: European group on tumor markers guidelines for clinical use. Int J Gynecol Cancer 15:679-691 (Pubitemid 41783071)
29. Cesta MF (2006) Normal structure, function, and histology of mucosa-associated lymphoid tissue (Review). Toxicol Pathol 34:599-608
30. Garson K, ShawTJ Clark KV, Yao DS, Vanderhyden BC (2005) Models of ovarian cancer - are we there yet? Mol Cell Endocrinol 239:5-26
31. Makrydimas G, Zagorianakou N, Zagorianakou P, Agnantis NJ (2003) CD44 family and gynaecological cancer. In Vivo 17:633-640 (Pubitemid 38165466)
32. Yamada J, Kitayama J, Tsuno NH, Yamashita H, Miyato H, Soma D, Otani K, Kamei T, Ishigami H, Hidemura A, Kaisaki S, Takahashi K, Nagawa H (2008) Intra-peritoneal administration of paclitaxel with non-animal stabilized hyaluronic acid as a vehicle - a new strategy against peritoneal dissemination of gastric cancer. Cancer Lett 272:307-315
33. Juaristi JA, Aguirre MV, Carmuega RJ, Romero-Benítez M, Alvarez MA, Brandan NC (2001) Hematotoxicity induced by paclitaxel: invitro and invivo assays during normal murine hematopoietic recovery. Method Find Exp Clin Pharmacol 23:161-167 (Pubitemid 32916731)
34. Aguirre MV, Todaro JS, Juaristi JA, Brandan NC (2010) Murine erythropoietic impairment induced by paclitaxel: interactions of GATA-1 and erythroid Krüppel-like transcription factors, apoptotic related proteins and erythropoietin receptor. Eur J Pharmacol 636:42-51